

			LABORATORY REPORT			
Name	:	Mr. Ananya J Desai		Reg. No	:	208100709
Sex/Age	:	Male/61 Years		Reg. Date	;	12-Aug-2022 08:22 AM
Ref. By	:			Collected On	:	12-Aug-2022 08:22 AM
Client Name	:	Mediwheel		Report Date	:	12-Aug-2022 03:47 PM

# **Medical Summary**

**GENERAL EXAMINATION** 

Height (cms): 175

Weight (kgs): 73.5

Blood Pressure: 110/70mmHg

Pulse: 90/Min

No Clubbing/Cynosis/Pallor/Pedel Oedem

Systemic Examination:

Cardio vascular System - S1,S2 Normal, No Murmur

Respiratory system - AEBE

Central Nervous System - No FND

Abdomen - Soft, Non Tender, No Organomegaly


Epilepsy – N/A




This is an electronically authenticated report

Dr.Jay Soni M.D, GENERAL MEDICINE

Page 3 of 4





Dr. Jay Soni M.D. (General Medicine) Reg. No.: G-23899







Reg. No : 208100709 Ref Id

Collected On

; 12-Aug-2022 08:22 AM

Name

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

: 61 Years

Tele No.

: 9877234003

Ref. By

**Parameter** 

MCV (Calculated)

MCH (Calculated)

MCHC (Calculated)

RDW (Calculated)

MPV (Calculated)

/ Male Pass. No.

Dispatch At

Location

: CHPL

Sample Type

: EDTA Whole Blood

Results COMPLETE BLOOD COUNT (CBC) Specimen: EDTA blood

Hemoglobin (Spectrophotometric 14.3 Measurement) Hematrocrit (Calculated) L 42.10

RBC Count (Volumetric Impedance) L 4.60

WBC Count (Volumetric Impedance)

g/dL %

million/cmm

Unit

13.0 - 18.0

Biological Ref. Interval

47 - 52

4.7 - 6.0 78 - 110

fL. Pg

27 - 31

%

31 - 35

L 10.8 6150

91.6

31.0

33.9

9.6

% /cmm 11.5 - 14.0 4000 - 10500

1L

7.4 - 10.4

**EXPECTED VALUES** DIFFERENTIAL WBC COUNT **EXPECTED VALUES** [Abs] [%] 2000 - 7000 Neutrophils (%) 55 % 42.0 - 75.2 3383 /cmm Lymphocytes (%) 30 % 20 - 451845 /cmm 1000 - 3000 Eosinophils (%) 05 % 0 - 6 615 /cmm 200 - 1000 Monocytes (%) 10 % 2 - 10 308 /cmm 20 - 500 Basophils (%) 00 % 0 - 1n /cmm 0 - 100

PERIPHERAL SMEAR STUDY

**RBC Morphology** 

Normocytic and Normochromic.

WBC Morphology

Normal

PLATELET COUNTS

Platelet Count (Volumetric Impedance)

264000

/cmm

150000 - 450000

**Platelets** 

Platelets are adequate with normal morphology.

**Parasites** 

Malarial parasite is not detected.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 05:20 PM Page 1 of 13

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709

Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Name

; Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

: 61 Years

: CHPL

Pass. No.

Tele No.

: 9877234003

Ref. By

/ Male

Dispatch At Sample Type

: EDTA Whole Blood

Location **Parameter** 

Result

Unit

Biological Ref. Interval

### **HEMATOLOGY**

#### BLOOD GROUP & RH

Specimen: EDTA and Serum; Method: Forward Reverse Tube Agglutination

**ABO** 

"O"

Rh (D)

Positive

Note

### **ERYTHROCYTE SEDIMANTATION RATE [ESR]**

ESR (After 1 hour)

Infra red measurement

02

mm/hr

ESR AT 1 hour: 1-7

ESR AT 2 hour: 8-15

#### ERYTHRO SEDIMENTION RATE, BLOOD -

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in prenancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (o-1mm) in polycythaemia, hypofibrinogenemia or or congestive cardiac failure and when there are abnormalities or the red cells such as poikilocytosis, spherocytosis or sickle cells.

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory,

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 2 of 13

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709

0709 **Ref Id** 

Collected On

: 12-Aug-2022 08:22 AM

Name

; Mr. Ananya J Desai

odi

Pass. No.

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

: 61 Years / Male

Tele No.

Unit

: 9877234003

Ref. By Location

: : CHPL Dispatch At Sample Type

: Flouride F,Flouride PP

Parameter

Result

Biological Ref. Interval

FASTING PLASMA GLUCOSE Specimen: Flouride plasma

Fasting Blood Sugar (FBS)

125.70

mg/dL

70 - 110

GOD-POD for glucose.

Criteria for the diagnosis of diabetes

1. HbA1c >/= 6.5 \*

Or

2. Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs.

3. Two hour plasma glucose >/= 200mg/dL during an oral glucose tolerence test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water.

4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >/= 200

\*In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

#### POST PRANDIAL PLASMA GLUCOSE

Specimen: Flouride plasma

Post Prandial Blood Sugar (PPBS)

123.8

mg/dL

70 - 140

GOD-POD for glucose.

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 3 of 13

CUROVIS HEALTHCARE PVT. LTD.



: CHPL



**TEST REPORT** 

Reg. No : 208100709

Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Name

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

: 61 Years / Male

Pass. No.

Tele No.

: 9877234003

Ref. By Location Dispatch At

Sample Type : Serum

		oumpio 13 p	7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Parameter	Result	Unit	Biological Ref. Interval
	Lipid Profile		
Cholesterol	141.00	mg/dL	Desirable: < 200 Boderline High: 200 - 239 High: > 240
Enzymatic, colorimetric method			
Triglyceride	185.70	mg/dL	Normal: < 150 Boderline High: 150 - 199 High: 200 - 499 Very High: > 500
Enzymatic, colorimetric method			
HDL Cholesterol	40.80	mg/dL	High Risk : < 40 Low Risk : = 60
Accelerator selective detergent method			
LDL	63.06	mg/dL	Optimal : < 100.0 Near / above optimal : 100-129 Borderline High : 130- 159 High : 160-189 Very High : >190.0
Calculated			· -
VLDL Calculated	37.14	mg/dL	15 - 35
LDL / HDL RATIO Calculated	1.55		0 - 3.5
Cholesterol /HDL Ratio	3.46		0 - 5.0

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 4 of 13





		TEST	REPORT		
Reg. No : 20810	00709	Ref Id	,	Collected On	: 12-Aug-2022 08:22 AM
Name : Mr. Ar	nanya J Desai			Reg. Date	: 12-Aug-2022 08:22 AM
Age/Sex : 61 Ye	ars / Male	Pass. No.	:	Tele No.	: 9877234003
Ref. By				Dispatch At	•
Location : CHPL			·	Sample Type	: Serum
Parameter			Result	Unit	Biological Ref. Interval
		BIO -	CHEMISTRY		
			<u>LFT '</u>	WITH GGT	
Total Protein Biuret Reaction			6.98	gm/dL	6.3 - 8.2
Albumin By Bromocresol Green			5.15	g/dL	0 - 4 days: 2.8 - 4.4 4 days - 14 yrs: 3.8 - 5.4 14 - 19 yrs: 3.2 - 4.5 20 - 60 yrs: 3.5 - 5.2 60 - 90 yrs: 3.2 - 4.6 > 90 yrs: 2.9 - 4.5
Globulin Calculated			1.83	g/dL	2.3 - 3.5
A/G Ratio Calculated			2.81		0.8 - 2.0
SGOT UV without P5P			25.10	U/L	0 - 40
SGPT UV without P5P			20.10	U/L	0 - 40
Alakaline Phosphata p - Nitrophenylphosphate (PNF)	ise P)		115.5	U/L	25 - 270
Total Bilirubin Vanadale Oxidation			0.48	mg/dL	0 - 1.2
Conjugated Bilirubir	1		0.16	mg/dL	0.0 - 0.4
Unconjugated Bilirul Sulph acid dpl/caff-benz	bin		0.32	mg/dL	0.0 - 1.1
GGT SZASZ Method			17.20	mg/dL	15 - 73

This is an electronically authenticated report.

Generated On: 12-Aug-2022 05:25 PM

\* This test has been out sourced.

SZASZ Method

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Approved On:

12-Aug-2022 01:55 PM Page 5 of 13

CUROVIS HEALTHCARE PVT. LTD.



: CHPL



**TEST REPORT** 

Reg. No : 208100709

Ref Id

Collected On

: 12-Aug-2022 08:22 AM

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex : 61 Years Ref. By

Name

Location

/ Male Pass. No. Tele No.

: 9877234003

Dispatch At

Sample Type

: Serum

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 6 of 13

CUROVIS HEALTHCARE PVT. LTD.





TE	ST	D	1	דם	-

Reg. No : 208100709 Ref Id

Pass. No.

Collected On

: 12-Aug-2022 08:22 AM

Name

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

Location

**UV Method** 

: 61 Years

: CHPL

/ Male

Tele No.

: 9877234003

Ref. By

Child: 5.0 - 18.0

Dispatch At

Sample Type : Serum

Result Unit Biological Ref. Interval **Parameter** 

**BIO - CHEMISTRY** 

Adult: 3.5 - 8.5 **Uric Acid** 4.60 mg/dL Enzymatic, colorimetric method Child: 2.5 - 5.5 Adult: 0.72 - 1.18 Creatinine 1.39 mg/dL Enzymatic Method Child: 0.5 - 1.0 BUN 12.30 mg/dL Adult: 7.0 - 20.0

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 7 of 13

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709 Ref Id

Collected On : 12-Aug-2022 08:22 AM

Name

Age/Sex

: Mr. Ananya J Desai

/ Male

: 61 Years

: CHPL

Reg. Date

: 12-Aug-2022 08:22 AM

Ref. By

Pass. No.

Tele No.

Unit

: 9877234003

Dispatch At

Sample Type

: EDTA Whole Blood

**Parameter** 

Location

Result

Biological Ref. Interval

# **HEMOGLOBIN A1 C ESTIMATION**

Specimen: Blood EDTA

\*Hb A1C

5.7

% of Total Hb

Normal: < 5.7 %

Pre-Diabetes: 5.7 % -

6.4 %

Diabetes: 6.5 % or

higher

Boronate Affinity with Fluorescent Quenching

Mean Blood Glucose

116,89

mg/dL

Calculated

## Degree of Glucose Control Normal Range:

Poor Control >7.0% \*

Good Control 6.0 - 7.0 %\*\*Non-diabetic level < 6.0 %

- \* High risk of developing long term complication such as retinopathy, nephropathy, neuropathy, cardiopathy, etc.
- \* Some danger of hypoglycemic reaction in Type I diabetics.
- \* Some glucose intolerant individuals and "subclinical" diabetics may demonstrate HbA1c levels in this area.

### **EXPLANATION:-**

- \*Total haemoglobin A1 c is continuously synthesised in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.
- \*The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose concentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels.
- \*The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days, HbA1c has been accepted as a measurnment which effects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.

\*It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

\*Errneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c(HbF) or differences in their glycation from that of HbA(HbS)

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 8 of 13

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709 Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Name

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

: 61 Years / Male

Tele No.

: 9877234003

Ref. By

Pass. No.

Dispatch At

: Urine Spot

**L**ocation

: CHPL

Sample Type

Test

Result

Unit

Biological Ref. Interval

#### URINE ROUTINE EXAMINATION

### **PHYSICAL EXAMINATION**

Quantity

15 cc

Colour

Pale Yellow

Clarity

Clear

## CHEMICAL EXAMINATION (BY REFLECTANCE PHOTOMETRIC)

pН

5

4.6 - 8.0

Sp. Gravity

1.015

1.001 - 1.035

Protein

Nil

Glucose

Nil

Ketone Bodies Urobilinogen

Nil

Bilirubin

Nil Nil

Nitrite

Blood

Nil

Nil

### MICROSCOPIC EXAMINATION (MANUAL BY MICROSCOPY)

Leucocytes (Pus Cells)

Occasional/hpf

Erythrocytes (Red Cells)

Nil

Epithelial Cells

Nil

/hpf

Crystals

Absent

Casts

Absent

Amorphous Material

Absent

Bacteria

Absent

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 9 of 13

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709

: Mr. Ananya J Desai

Name

: CHPL

Age/Sex Ref. By

Location

: 61 Years

/ Male

Pass. No.

Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Reg. Date

: 12-Aug-2022 08:22 AM

Tele No.

: 9877234003

Dispatch At

Sample Type

: Urine Spot

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 10 of 1

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709 Ref Id

Collected On : 12-Aug-2022 08:22 AM

Name

Age/Sex

: Mr. Ananya J Desai

: 61 Years

: CHPL

/ Male

Reg. Date Pass. No.

Tele No.

: 12-Aug-2022 08:22 AM

Ref. By

: 9877234003

Dispatch At

Sample Type

: Serum

Location **Parameter** 

Result

Unit

Biological Ref. Interval

### **IMMUNOLOGY**

#### THYROID FUNCTION TEST

T3 (Triiodothyronine)

CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY

1.00

ng/mL

0.6 - 1.81

Triiodothyronine (T3) is a hormone synthesized and secreted by the thyroid gland in response to the pituitary hormone TSH (thyroid stimulating hormone) and is regulated by a negative feedback mechanism involving the thyroid gland, pituitary gland and hypothalamus.

In the circulation, 99.7% of T3 is reversibly bond to transport proteins, primarily thyroxine-binding globulin (TBG) and to a lesser extent albumin and prealbumin. The remaining unbound T3 is free in the circulation and is metabolically active.

In hypothyroidism and hyperthyroidism, F T3 (free T3) levels parallel changes in total T3 levels. Measuring F T3 is useful in certain conditions such as normal pregnancy and steroid therapy, when altered levels of total T3 occur due to changes in T3 binding proteins, especially TBG.

T4 (Thyroxine)

CHEMILÚMINESCENT MICROPARTICLE IMMUNOASSAY

7.40

ng/mL

3.2 - 12.6

Thyroxin (T4) is a hormone synthesized and secreted by the thyroid gland in response to the pituitary hormone TSH (thyroid stimulating hormone) and is regulated by a negative feedback mechanism involving the thyroid gland, pituitary gland and hypothalamus. In the circulation, 99,95% of T4 is reversibly bond to transport proteins, primarily thyroxine-binding globulin (TBG) and to a lesser extent albumin and thyroxine-binding prealbumin. The remaining unbound T4 is free in the circulation and is both metabolically active and a precursor to triiodothyronine (T3).

In hypothyroidism and hyperthyroidism, F T4 (free T4) levels parallel changes in total T4 levels. Measuring FT4 is useful in certain conditions such as normal pregnancy and steroid therapy, when altered levels of total T4 occur due to changes in T4 binding proteins, especially TBG.

#### Limitations:

- 1. The anticonvulsant drug phenytoin may interfere with total and F T4 levels due to competition for TBG binding
- 2.F T4 values may be decreased in patients taking carbamazepine.
- 3. Thyroid autoantibodies in human serum may interfere and cause falsely elevated F T4 results.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 11 of 1

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709 Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Name

: Mr. Ananya J Desai

Reg. Date

: 12-Aug-2022 08:22 AM

Age/Sex

Location

: 61 Years

Pass. No.

Tele No.

: 9877234003

Ref. By

/ Male

Dispatch At

Sample Type

: Serum

\*TSH

: CHPL

2.055

μIU/ml

0.55 - 4.78

CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY

Thyroid stimulating hormone (TSH) is synthesized and secreted by the anterior pituitary in response to a negative feedback mechanism involving concentrations of FT3 (free T3) and FT4 (free T4). Additionally, the hypothalamic tripeptide, thyrotropin-relasing hormone (TRH), directly stimulates TSH production. TSH stimulates thyroid cell production and hypertrophy, also stimulate the thyroid gland to synthesize and secrete T3 and T4. Quantification of TSH is significant to differentiate primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

TSH levels During Pregnancy: First Trimester :0.1 to 2.5 µIU/mL Second Trimester: 0.2 to 3.0 µIU/mL Third trimester: 0.3 to 3.0 µIU/mL

Referance: Carl A.Burtis, Edward R.Ashwood, David E.Bruns. Tietz Textbook of Clinical Chemistry and Molecular

Diagnostics. 5th Eddition. Philadelphia: WB Sounders, 2012:2170

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. CHPt, will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 12 of 1

CUROVIS HEALTHCARE PVT. LTD.





Reg. No : 208100709

: Mr. Ananya J Desai

: 61 Years

/ Male

Pass. No.

Ref Id

Collected On

: 12-Aug-2022 08:22 AM

Reg. Date

: 12-Aug-2022 08:22 AM

Tele No.

: 9877234003

Dispatch At

Sample Type

Unit

: Serum

Location : CHPL

Name

Age/Sex

Ref. By

Parameter

Result

Biological Ref. Interval

IMMUNOLOGY

\*TOTAL PROSTATE SPECIFIC ANTIGEN (PSA)

0.91

ng/mL

0 - 4

CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY

Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-8 ng/mL.

Percentage of free PSA = free PSA/total PSA X 100

Percentage of free PSA: Patients with prostate cancer generally have a lower percentage of Free PSA than patients with benign prostatic hyperplasia. Percentage Free PSA of less than 25% is a high likelihood of prostatic cancer.

----- End Of Report -----

# For tests performed on specimens received or collected from non-CHPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/lest request and such verification has been carried out at the point generation of the said specimen by the sender. CHPL will be responsible only for the analytical part of the test carried out. All other responsibility will be of referring laboratory.

This is an electronically authenticated report.

\* This test has been out sourced.

Approved By:

Dr.Dhwani Bhatt

MD (Pathology)

Generated On: 12-Aug-2022 05:25 PM

Approved On:

12-Aug-2022 01:55 PM Page 13 of 1

CUROVIS HEALTHCARE PVT. LTD.



			LABORATORY REPORT			
Name	•	Mr. Ananya J Desai		Reg. No	•	208100709
Sex/Age	:	Male/61 Years		Reg. Date	:	12-Aug-2022 08:22 AM
Ref. By	;			Collected On	:	12-Aug-2022 08:22 AM
<b>Client Name</b>	:	Mediwheel		Report Date	;	12-Aug-2022 03:47 PM

# Electrocardiogram

## **Findings**

Normal Sinus Rhythm.

Within Normal Limit.




This is an electronically authenticated report

Dr.Jay Soni

M.D, GENERAL MEDICINE

Page 1 of 4





			LABORATORY REPORT			
Name	:	Mr. Ananya J Desai		Reg. No	:	208100709
Sex/Age	:	Male/61 Years		Reg. Date	:	12-Aug-2022 08:22 AM
Ref. By	;			Collected On	:	12-Aug-2022 08:22 AM
Client Name	;	Mediwheel		Report Date	;	12-Aug-2022 03:47 PM

## 2D Echo Colour Doppler

### **OBSERVATION:**

- 2 D Echo and color flow studies were done in long and short axis, apical and Sub coastal views.
- 1. Normal LV size. No RWMA at rest.
- 2. Normal RV and RA. Concentric LVH.
- 3. All Four valves are structurally normal.
- 4. Good LV systolic function. LVEF = 60%.
- 5. Reduced LV Compliance.
- Trivial TR. Mild MR. No AR.
- 7. Mild PAH. RVSP = 46 mmHG.
- 8. Intact IAS and IVS.
- 9 No Clot, No Vegetation
- 10. No pericardial effusion.

#### CONCLUSION

- Normal LV size with Good LV systolic function.
- 2. Concentric LVH . Reduced LV Compliance
- 3. Trivial TR with Mild PAH. Mild MR. No AR
- 4. No RWMA at rest.

This echo doesn't rule out any kind of congenital cardiac anomalies.



This is an electronically authenticated report

Dr.Jay Soni

M.D, GENERAL MEDICINE

Page 2 of 4



			LABORATORY REPORT		
Name	:	Mr. Ananya J Desai	Reg. No	;	208100709
Sex/Age	:	Male/61 Years	Reg. Date	:	12-Aug-2022 08:22 AM
Ref. By	:		Collected	On :	
Client Name	:	Mediwheel	Report Da	te :	12-Aug-2022 04:58 PM

## X RAY CHEST PA

Prominent Broncho-vascular margins Noted in right hilar region.

Rest of Both lung fields appear clear.

No evidence of any active infiltrations or consolidation.

Cardiac sized appears normal in size.

Both costo-phrenic angles appear free of fluid.

Both domes of diaphragm appear normal.

----- End Of Report -----

This is an electronically authenticated report

<del>25---</del>

DR DHAVAL PATEL
Consultant Radiologist
MB,DMRE
Reg No:0494



Page 3 of 3



			LABORATORY REPORT			
Name	:	. Mr. Ananya J Desai		Reg. No	:	208100709
Sex/Age	;	Male/61 Years		Reg. Date	:	12-Aug-2022 08:22 AM
Ref. By	:			Collected On	:	
Client Name	:	Mediwheel		Report Date	:	12-Aug-2022 04:56 PM

## **USG ABDOMEN**

**Liver** appears normal (14.5 cm) in size, show **increased parenchymal echoes**. No evidence of focal solid or cystic lesion seen. No evidence of dilatation of intra-hepatic billiary or portal radicals. PV is normal in caliber.

**Gall bladder** is normally distended and **shows few tiny hyperechoic foci without posterior acoustic shadowing seen within largest measuring 5 mm. P/O ? GB polyp.** No evidence of calculus seen. Gall bladder wall thickness appears normal.

Pancreas appears normal in size and echopattern. No evidence of focal lesions.

Spleen appears normal in size & normal in echopattern. No evidence of focal lesions.

**Both kidneys** are normal in size, shape and position. C.M. differentiation on both sides is maintained.

Evidence of app. 26 x 23 mm sized anechoic cortical cyst with internal thin septa noted in mid pole of right kidney. Suggest Right Renal Cortical Cyst.

No evidence of hydronephrosis, calculus or solid mass on either side.

**Urinary bladder** contour is normal, No evidence of calculus or mass.

**Prostate** is normal in size, show homogenous echo, outline is smooth.

No paraaortic lymphadenopathy seen.

No evidence of dilated small bowel loops.

COMMENTS:
GRADE I FATTY LIVER.

This is an electronically authenticated report

925\_-

DR DHAVAL PATEL
Consultant Radiologist
MB,DMRE
Reg No:0494



Page 1 of 3

# CUROVIS HEALTHCARE PVT. LTD.



			LABORATORY REPORT			
Name	:	Mr. Ananya J Desai		Reg. No	;	208100709
Sex/Age	:	Male/61 Years		Reg. Date	:	12-Aug-2022 08:22 AM
Ref. By	:			Collected On	:	
Client Name	:	Mediwheel		Report Date	:	12-Aug-2022 04:56 PM

RIGHT RENAL CORTICAL CYST.

P/O ? GB POLYP as described above.

This is an electronically authenticated report

93...

DR DHAVAL PATEL Consultant Radiologist MB,DMRE Reg No:0494



Page 2 of 3



			LABORATORY REPORT			
Name	:	Mr. Ananya J Desai		Reg. No	:	208100709
Sex/Age	:	Male/61 Years		Reg. Date	;	12-Aug-2022 08:22 AM
Ref. By	:			Collected On	:	12-Aug-2022 08:22 AM
Client Name	:	Mediwheel		Report Date	;	12-Aug-2022 03:08 PM

# Eye Check - Up

No Eye Complaints

RIGHT EYE

SP: +0.75

CY: -0.75

AX: 05

LEFT EYE

SP: +1.00

CY: -0.75

AX:05

	Without Glasses	With Glasses
Right Eye	6/5	N.A
Left Eye	6/5	N.A

Near Vision: Right Eye - N/6, Left Eye - N/6

Fundus Examination - Within Normal Limits.

Color Vision: Normal

Comments: Normal

AHMEDABAD S

----- End Of Report --

This is an electronically authenticated report

Dr Kejal Patel MB,DO(Ophth)

Page 4 of 4





CLIENT NAME: ANANYA DESAI.

AGE: 61Y/ M

Date: 10/08/2022.

# **AUDIOGRAM**





MODI	E Air Cor	nduction	Bone Co	Colour								
EAR	Masked	UnMasked	Masked	unMaskeri	Code							
LEFT		Х	I	>	Blue							
RIGHT	Δ	0	Ľ	<	Red							
NO RESPON	NO RESPONSE: Add 4 below the respective symbols											

Threshold In dB	RIGHT	LEFT
AIR CONDUCTION	10.5	10.5
BONE CONDUCTION	***************************************	
SPEECH		

#### Comments:-

Bilateral Hearing Sensitivity Within Normal Limits.

